Sartorius Stedim Biotech S.A. (ADR)
General ticker "SRTOY" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $21.2B (TTM average)
Sartorius Stedim Biotech S.A. (ADR) follows the US Stock Market performance with the rate: 24.6%.
Estimated limits based on current volatility of 2.0%: low 17.99$, high 18.72$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-04-04, amount 0.08$ (Y0.43%)
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.24$, 28.23$]
- 2026-12-31 to 2027-12-31 estimated range: [15.10$, 27.94$]
Financial Metrics affecting the SRTOY estimates:
- Positive: with PPE of 126.3 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 18.50 > 18.38
- Negative: Industry operating profit margin (median), % of -2.56 <= 3.01
- Negative: Operating cash flow per share per price, % of 0.26 <= 6.64
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: -0.01 < Industry operating cash flow per share per price (median), % of 1.99
- Negative: Industry inventory ratio change (median), % of 0.37 > 0.31
- Positive: Inventory ratio change, % of -4.26 <= -0.75
Short-term SRTOY quotes
Long-term SRTOY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €2,775.50MM | €2,780.00MM | €2,850.38MM |
| Operating Expenses | €2,291.00MM | €2,409.40MM | €2,323.05MM |
| Operating Income | €484.50MM | €370.60MM | €527.33MM |
| Non-Operating Income | €-83.40MM | €-151.40MM | €-168.86MM |
| Interest Expense | €121.10MM | €158.90MM | €146.67MM |
| R&D Expense | €129.50MM | €144.10MM | €0.00MM |
| Income(Loss) | €401.10MM | €219.20MM | €358.47MM |
| Taxes | €89.00MM | €40.70MM | €103.07MM |
| Profit(Loss)* | €309.70MM | €175.10MM | €255.12MM |
| Stockholders Equity | €2,638.50MM | €3,986.60MM | €4,088.76MM |
| Inventory | €882.40MM | €684.90MM | €690.61MM |
| Assets | €7,739.90MM | €8,256.40MM | €8,013.99MM |
| Operating Cash Flow | €746.40MM | €815.10MM | €517.34MM |
| Capital expenditure | €473.60MM | €339.80MM | €377.68MM |
| Investing Cash Flow | €-2,722.70MM | €-340.00MM | €-382.00MM |
| Financing Cash Flow | €1,986.10MM | €84.90MM | €-373.84MM |
| Earnings Per Share** | €0.34 | €0.18 | €0.03 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.